General MedicationsORALGeneric

IMIPRAMINE PAMOATE

Standard Dose

EQ 125MG HYDROCHLORIDE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview IMIPRAMINE PAMOATE is listed in Drugs@FDA under application 202338 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient IMIPRAMINE PAMOATE Form and strength CAPSULE;ORAL - EQ 125MG HYDROCHLORIDE Sponsor RISING Submission history Latest submission status date: 2025-06-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview IMIPRAMINE PAMOATE is listed in Drugs@FDA under application 202338 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IMIPRAMINE PAMOATE Form and strength CAPSULE;ORAL - EQ 125MG HYDROCHLORIDE Sponsor RISING Submission history Latest submission status date: 2025-06-24 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.